The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder
Open accessAbstract
Methamphetamine (MA) triggers neuroinflammation and medications that counteract MA-induced neuroinflammation may reduce MA-induced neurodegeneration and improve neurocognition and treatment outcomes in MA use disorder. We performed a randomized, placebo-controlled trial to determine the safety and efficacy of ibudilast (IBUD), a phosphodiesterase inhibitor that reduces neuroinflammation, for the treatment of MA use disorder. Treatment-seeking volunteers with MA use disorder were randomly assigned to receive 12 weeks of IBUD 50 mg twice daily (N = 64) or placebo (N = 61) with medication management counseling. Participants visited the outpatient research clinic twice weekly to provide urine specimens for drug screens and undergo study assessments. The primary outcome was end of treatment MA-abstinence (EOTA) during weeks 11 and 12 of treatment. Serum IBUID levels were measured for IBUD participants during week 3 of treatment. There was no difference in EOTA for IBUD (14%) versus placebo (16%, p > 0.05). There was no correlation between serum IBUD levels and MA use during treatment and mean IBUD levels for participants with (mean = 51.3, SD = 20.3) and without (mean = 54.7, SD = 33.0, p = 0.70) EOTA. IBUD was well tolerated. IBUD did not facilitate MA abstinence in this outpatient trial. Whether targeting neuroinflammation, either with IBUD in other subgroups of MA users or clinical trial designs, or with other anti-inflammatory medications, is an effective strategy for treating MA use disorder is not clear. Graphical Abstract The proportion of urine drug screens negative for methamphetamine (MA) during the two week lead-in period (weeks -2 and - 1) and the 12 week medication treatment period (weeks 1-12) for ibudilast versus placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For both ibudilast and modafinil, these early signals on improving cognitive function, however, have no signal for reducing MA use in larger randomized controlled trials (98, 99).”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
Polazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984 · cited 2×
“Multiple studies implicate neuroinflammatory processes in the pathophysiology of a variety of neuropsychiatric conditions (Hirsch and Hunot 2009; Sidoryk-Wegrzynowicz et al. 2011), including MA use disorder (Kohno et al. 2019).”
Structured Clinical Interview for DSM-IV
(2007) · Encyclopedia of Measurement and Statistics · doi:10.4135/9781412952644.n443 · Cited by 718
Sobell, M. B., Sobell, L. C., Klajner, F., Pavan, D., & Basian, E. (1986) · Addictive Behaviors · doi:10.1016/0306-4603(86)90040-7 · Cited by 467
Ensuring balanced distribution of prognostic factors in treatment outcome research.
Stout, R. L., Wirtz, P. W., Carbonari, J. P., & Del Boca, F. K. (1994) · Journal of Studies on Alcohol, Supplement · doi:10.15288/jsas.1994.s12.70 · Cited by 461
Parkinson's disease: Autoimmunity and neuroinflammation
De Virgilio, A., Greco, A., Fabbrini, G., Inghilleri, M., Rizzo, M. I., Gallo, A., Conte, M., Rosato, C., Ciniglio Appiani, M., & de Vincentiis, M. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.022 · Cited by 389
Methamphetamine causes microglial activation in the brains of human abusers
Sekine, Y., Ouchi, Y., Sugihara, G., Takei, N., Yoshikawa, E., Nakamura, K., Iwata, Y., Tsuchiya, K. J., Suda, S., Suzuki, K., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1179-08.2008 · Cited by 381 · cited 1×
“In a human imaging study, a marker for activated microglia was significantly increased in abstinent MA users versus non-using controls and binding levels correlated inversely with the duration of MA abstinence (Sekine et al. 2008).”
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
Fox, R. J., Coffey, C. S., Conwit, R., Cudkowicz, M. E., Gleason, T., Goodman, A., Klawiter, E. C., Matsuda, K., McGovern, M., Naismith, R. T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803583 · Cited by 286
Research works printed but not linked: 2
- Pettinati HM, National Institute on Alcohol Abuse and Alcoholism (U.S.) (2004) Medical management treatment manual : a clinical research guide for medically trained clinicians providing pharmacotherapy as part of the treatment for alcohol dependence. U.S. Dept. of Health and Human Services, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, Bethesda
- Spitzer R, Williams J, Gibbbon M, First M (1995) The structured clinical interview for DSM-IV. American Psychiatric Press, Washington, DC
Cited by
Li, Y., Li, Y., & Zhu, Z. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1284214 · Cited by 45
Clinical management of psychostimulant withdrawal: review of the evidence
Li, M. J., & Shoptaw, S. J. (2023) · Addiction · doi:10.1111/add.16093 · Cited by 39
Self-citationToll-Like Receptor 4 Signaling and Drug Addiction
Wu, R., & Li, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.603445 · Cited by 42
“However, a most recent study showed that ibudilast did not affect methamphetamine abstinence (Heinzerling et al., 2020).”
BackgroundPharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets
Yates, J. R. (2024) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s431273 · Cited by 32
“Ibudilast does not facilitate METH abstinence, 593 but it decreases peripheral markers of inflammation associated with METH use.”
BackgroundRole of Microglia in Psychostimulant Addiction
da Silva, M. C. M., Iglesias, L. P., Candelario‐Jalil, E., Khoshbouei, H., Moreira, F. A., & de Oliveira, A. C. P. (2022) · Current Neuropharmacology · doi:10.2174/1570159x21666221208142151 · Cited by 29
Metadata
- Authors
- Heinzerling, K. G., Briones, M., Thames, A. D., Hinkin, C. H., Zhu, T., Wu, Y. N., & Shoptaw, S. J.
- Affiliations
- University of California, Los Angeles (US)
- University of Southern California (US)
- Corresponding author
- Heinzerling, Keith G.
- Venue
- Journal of Neuroimmune Pharmacology
- Published
- 2019-12-09
- Volume
- 15
- Issue
- 2
- Pages
- 238-248
- ISSN
- 1557-1890 (ISSN-L)
- 1557-1904
- PMC
- PMC8651052
- OpenAlex
- W2994833118
- Cited by
- 30
- References
- 52
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 9 · 2023: 3 · 2022: 8 · 2021: 2 · 2020: 2
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Journal of Neuroimmune Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute on Drug Abuse (DA035054)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- ibudilast, methamphetamine dependence, neuroinflammation, phosphodiesterase inhibitors, abstinence, anti-inflammatory pharmacotherapy, medication adherence, serum drug concentration
- MeSH terms
- Adult, Central Nervous System Stimulants, Double-Blind Method, Female, Humans, Indolizines, Male, Methamphetamine, Middle Aged, Phosphodiesterase Inhibitors, Pyrazoles, Pyridines, Treatment Outcome, Inflammation Mediators, Amphetamine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder. https://app.cochat.ai/papers/10.1007/s11481-019-09883-w
- The paper
- Heinzerling, K. G., Briones, M., Thames, A. D., Hinkin, C. H., Zhu, T., Wu, Y. N., & Shoptaw, S. J. (2020). Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder. Journal of Neuroimmune Pharmacology. https://doi.org/10.1007/s11481-019-09883-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.